Enrolling by Invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003
- Conditions
- Adenocarcinoma, Breast Diseases, Breast Neoplasms, +54 more
- Locations
-
- UCSF Medical Center San Francisco, California, United States
- Yale Cancer Center New Haven, Connecticut, United States
- START Midwest Grand Rapids, Michigan, United States
- Memorial Sloan Kettering Cancer Center New York, United States